<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975998</url>
  </required_header>
  <id_info>
    <org_study_id>16/743</org_study_id>
    <nct_id>NCT03975998</nct_id>
  </id_info>
  <brief_title>Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation</brief_title>
  <acronym>Dutch-AMR</acronym>
  <official_title>Dutch-AMR Study: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation and Preserved Ejection Fraction: a Multicenter Registry Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Severe asymptomatic organic Mitral Valve (MV) regurgitation with preserved left ventricular
      (LV) function is a challenging clinical entity as data on the recommended treatment strategy
      for these patients are scarce and conflicting, which is reflected in current guidelines.
      European guidelines advocate a more conservative strategy i.e. watchful waiting, with yearly
      echocardiography, whilst American guidelines are more in favour of early surgery to
      reconstruct the MV, i.e. MV repair (in contrast to MV replacement) in order to prevent future
      LV dysfunction and complaints.

      A number of non-randomised trials show a favourable outcome of early surgery: in the study of
      Enriquez-Sarano et al. for instance, the early surgery strategy has shown to be associated
      with improved long-term survival, decreased cardiac mortality, and decreased morbidity
      compared with the conservative management [1]. On the other hand, non-randomised trials
      describe also that a conservative strategy (i.e. watchful waiting) can be safely
      accomplished. If facilitated surgery is performed in this population (50% at 10 years
      follow-up according to Rosenhek et al [2]), it has proven to be eventually associated with
      good perioperative and postoperative outcome when careful follow-up is being carried out [2].

      Objective:

      To compare early MV repair versus watchful waiting in asymptomatic patients with severe
      organic mitral valve regurgitation and preserved left ventricular function.

      Study design:

      Multicenter, registry trial.

      Study population:

      250 Asymptomatic patients (18-75 years old) with severe organic MV regurgitation and
      preserved left ventricular function. The current European Society of Cardiology (ESC)
      guidelines on Valvular Heart Disease will be applied [3]. These guidelines are also used in
      the Netherlands. Accordingly, patients with an indication for MV surgery will not be
      included.

      Intervention:

      Intervention will be early MV repair compared to a watchful waiting strategy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2031</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Time to event: cardiovascular mortality, congestive heart failure, hospitalization, class I or class IIa indication for MV surgery</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Aymptomatic patients with severe mitral regurgitation</arm_group_label>
    <description>Watchful waiting Early Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mitral valve repair</intervention_name>
    <description>Minimally invasive repair of severe organic mitral regurgiation</description>
    <arm_group_label>Aymptomatic patients with severe mitral regurgitation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Asymptomatic patients with severe organic mitral regurgitation and preserved ejection
        fraction.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years.

          -  Asymptomatic patients. &quot;Asymptomatic&quot; is defined as absence of subjective limitations
             of exercise capacity or complaints expressed by the patient and confirmed by the
             treating cardiologist.

          -  Severe organic mitral valve regurgitation. &quot;Severe organic mitral valve regurgitation&quot;
             is defined as non-ischemic mitral valve regurgitation with an organic cause (intrinsic
             valve lesion) as determined by echocardiographic core-lab reading based on the
             criteria for definition of severe MR as issued by the ESC guidelines [4]. For
             practical reasons, referring cardiologists can use an ESC guidelines based index that
             was validated in the investigator's core-lab (Jansen et al, Practical
             echocardiographic semi-quantitative scoring system to determine severity of mitral
             regurgitation. Abstract presentation at ESC EUROECHO Congress 2011 and annual spring
             congress 2012 Netherlands Society of Cardiology).

          -  Preserved left ventricular function, &quot;Preserved left ventricular function&quot; is defined
             as left ventricular ejection fraction &gt;60% and left ventricular end-systolic dimension
             &lt;45 mm (no indexed value, measured by echocardiography).

          -  The likelihood of MV repair should be more than 90% determined by the local heart team
             with a cardiologist and cardiothoracic surgeon.

        Exclusion Criteria:

          -  Pulmonary hypertension (&gt;50 mmHg at rest).

          -  Atrial fibrillation, either on 12-lead ECG or holter-monitoring.

          -  Physical inability as determined by the heart team to undergo surgery.

          -  Other life-threatening morbidity.

          -  Higher expected surgical risks in advance, according to the dedicated heart team.

          -  Patients with moderate to severe kidney disease (estimated glomerular filtration rate
             (eGFR) less than 30 mL/min).

          -  Flail leaflet together with a left ventricular end systolic diameter (LVESD) â‰¥40 mm
             (no indexed value)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Amsterdam Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthijs Boekholdt</last_name>
      <email>s.m.boekholdt@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Jolanda Kluin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthijs Boekholdt</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rene van den Brink</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Breda</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Schaap</last_name>
      <email>jschaap@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>Jeroen Schaap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente (MST)</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lodewijk Wagenaar</last_name>
      <email>L.Wagenaar@mst.nl</email>
    </contact>
    <investigator>
      <last_name>Lodewijk Wagenaar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center (LUMC)</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bas Streukens</last_name>
      <email>bas.streukens@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMC Utrecht)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven AJ Chamuleau, MD, PhD</last_name>
      <phone>0031 88 75 59801</phone>
      <email>S.A.J.Chamuleau@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Steven AJ Chamuleau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Einar A Hart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maarten Jan M Cramer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Ling LH, Enriquez-Sarano M, Seward JB, Orszulak TA, Schaff HV, Bailey KR, Tajik AJ, Frye RL. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation. 1997 Sep 16;96(6):1819-25.</citation>
    <PMID>9323067</PMID>
  </reference>
  <reference>
    <citation>Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006 May 9;113(18):2238-44. Epub 2006 May 1.</citation>
    <PMID>16651470</PMID>
  </reference>
  <reference>
    <citation>Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007 Jan;28(2):230-68. Epub 2007 Jan 26.</citation>
    <PMID>17259184</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>S.A.J. Chamuleau</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Mitral regurgitation</keyword>
  <keyword>Mitral repair</keyword>
  <keyword>Watchful waiting</keyword>
  <keyword>Asymptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

